Granules India seeking first-to-file status for Ruxolitinib Extended-Release Tablets
FROM THE WIRE · THEHINDUBUSINESSLINE.COM
Granules India seeks first-to-file status for Ruxolitinib Extended-Release Tablets, potentially securing 180 days of US generic exclusivity pending FDA review.
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishPotential 180-day US generic exclusivity could support future company growth.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Granules India seeks first-to-file status for Ruxolitinib Extended-Release Tablets.
- 02Approval would grant 180 days of US generic exclusivity.
- 03FDA review decision is still pending for this formulation.